Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00635609 · ClinicalTrials.gov registry record · Phase 4
Treatment of Acne Vulgaris With Doryx Tablets Compared to Doxycyline Hyclate
A Phase 4 study, sponsored by Warner Chilcott.
- Completed
- Registry status
- Phase 4
- Development phase
- 93
- Enrollment target
NCT00635609: Completed Phase 4 study, sponsored by Warner Chilcott.
NCT00635609 is a Phase 4 study that has completed, run by Warner Chilcott. The registered enrollment target is 93 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (82% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00635609, a Phase 4 study, has completed, sponsored by Warner Chilcott.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 93 participants
- Enrollment target
Study Summary
Randomized, multi-center, open label, active-comparator study to compare the efficacy and tolerability of Doryx Delayed Release Tablets to doxycycline hyclate in patients with moderate to severe acne vulgaris.
Primary Outcome
The Investigator's Global Assessment (IGA) was performed at baseline and at 12 weeks. The IGA score is based on a 5-point acne severity scale from zero (clear) to 4 (severe). Successful outcome is at least a 2-point reduction in IGA score from baseline to 12 weeks.
Interventions
- DRUG Doxycycline hyclate
- DRUG Doxycycline hyclate (Doryx)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 93 participants |
| Start Date | 2008-03 |
| Est. Completion | 2008-09 |
| Phase | Phase 4 |
What the finished NCT00635609 record still lists
NCT00635609 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 93 participants, a relatively small participant target, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (82% lower).
The record links to 0 conditions, and to 2 interventions - of which Doxycycline hyclate is the first listed.
NCT00635609 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00635609 about?
NCT00635609 is a clinical study titled "Treatment of Acne Vulgaris With Doryx Tablets Compared to Doxycyline Hyclate". Randomized, multi-center, open label, active-comparator study to compare the efficacy and tolerability of Doryx Delayed Release Tablets to doxycycline hyclate in patients with moderate to severe acne vulgaris.
What is the current status of trial NCT00635609?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 93 participants. The study started on 2008-03. Estimated completion is 2008-09.
What interventions are being tested in trial NCT00635609?
The interventions under investigation include: Doxycycline hyclate (DRUG), Doxycycline hyclate (Doryx) (DRUG).
Who is sponsoring clinical trial NCT00635609?
This trial is sponsored by Warner Chilcott, which has 53 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00635609's enrollment target sits among peer trials
93 874th of 2000 higher than 1,125 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02203526 · 93 participants · Phase 1
Phase 1 Study of Ibrutinib and Immuno-Chemotherapy Using Temozolomide, Etoposide, Doxil, Dexamethasone, Ibrutinib,Rituximab (TEDDI-R) in Primary CNS Lymphoma
- NCT03089554 · 93 participants · Phase 2
Evaluating Genomic Testing in Human Cancer & Outcomes of Targeted Therapies
- NCT05000021 · 93 participants · NA
Reducing Diabetes Distress Using Cognitive Behavioral Therapy in Young Adults With Type 1 Diabetes
- NCT05489887 · 93 participants · Phase 2
Naxitamab Added to Induction for Newly Diagnosed High-Risk Neuroblastoma
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia